Log In
Print
BCIQ
Print
Print this Print this
 

Rifamycin SV MMX (CB-01-11)

  Manage Alerts
Collapse Summary General Information
Company Cosmo Pharmaceuticals S.p.A.
DescriptionBroad-spectrum, semisynthetic, orally non-absorbable antibiotic formulated with MMX multi-matrix system technology
Molecular Target
Mechanism of Action 
Latest Stage of DevelopmentPhase III
IndicationDiarrhea (infectious)
Partner

Dr. Falk Pharma GmbH; Santarus Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today